



IPW

Practitioner's Desk No. 2003DE409

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dahlmann, et al.

Application No.: 10/783,407

Group No.:

Filed: February 20, 2004

For: Corrosion and Gas Hydrate Inhibitors Having Improved Water Solubility And Increased Biodegradability

Commissioner for Patent  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

**CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10\***  
(When using *Express Mail*, the *Express Mail* label number is **mandatory**;  
*Express Mail* certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

[ ] deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10\*

[ ] with sufficient postage as first class mail.

[ ] as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_ (mandatory)

TRANSMISSION

[ ] transmitted by facsimile to the Patent and Trademark Office (703) \_\_\_\_-\_\_\_\_.

Date: May 14, 2004

Jackie L. Wise  
Signature  
Jackie L. Wise  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).  
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.


Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
  - 1a. ☒ Form PTO-1449.
  - 1b. ☒ Copies of Information Disclosure Statement citations.
  - 1c. ☐ PCT Search Report .
  - 1d. ☒ Copies of Co-pending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☐ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

7. ☒ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. ☒ In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:
- a. U.S. Serial no. 10/483,785, filed 1/13/04, Dahlmann et al.
  - b. U.S. Serial no. 10/483,838, filed 1/13/04, Dahlmann et al.
  - c. U.S. Serial no. 10/783,153, filed 2/20/04, Dahlmann et al.
  - d. U.S. Serial no. 10/783,188, filed 2/20/04, Dahlmann et al.
  - e. U.S. Serial no. 10/783,189, filed 2/20/04, Dahlmann et al.
  - f. U.S. Serial no. 10/783,724, filed 2/20/04, Dahlmann et al.


Respectfully submitted,

  
\_\_\_\_\_  
Anthony A. Bisulca  
Registration No. 40,913

**CUSTOMER NO. 25,255**

Clariant Corporation  
Industrial Property Department  
4000 Monroe Road  
Charlotte, North Carolina 28205  
Telephone: 704/331-7151  
Facsimile: 704/331-7707

MAY 18 2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (37 CFR 1.98(b))		ATTY. DOCKET NO. 2003DE409	SERIAL NO. 10/783,407
		APPLICANT: Dahlmann, et al.	
		FILING DATE: 2/20/04	GROUP:

## U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	US 4,730,079	3/8/88	Hofinger et al.	560	196	
	AB	US 4,997,912	3/5/91	Wirtz et al.	530	232	
	AC	US 5,135,668	8/4/92	Larsen	252	8.555	
	AD	US 5,432,292	7/11/95	Sloan, Jr.	585	15	
	AE	US 5,460,728	10/24/95	Klomp et al.	210	698	
	AF	US 5,600,044	2/4/97	Colle et al.	585	15	
	AG	US 5,648,575	7/15/97	Klomp et al.	585	15	
	AH	US 6,025,302	2/15/00	Pakulski	507	90	
	AI	US 6,102,986	8/15/00	Klug	95	153	
	AJ	US 6,152,993	11/28/00	Klomp	95	153	
	AK	US 6,177,497	1/23/01	Klug et al.	524	376	
	AL	US 6,261,346	7/17/01	Breuer et al.	106	14.15	
	AM	US 6,369,004	4/9/02	Klug et al.	507	90	
	AN	US 6,372,918	4/16/02	Feustel et al.	548	349.1	
	AO	US 6,379,294	4/30/02	Buijs et al.	584	114	
	AP	US 6,566,309	5/20/03	Klug et al.	507	90	
	AQ	US 2003/0013614	1/16/03	Klug et al.	507	200	
	AR	US 2004/0030206	2/12/04	Dahlmann et al.	585	15	
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION							
		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION
	BA	EP 0 212 265	3/4/87	Europe			See AA above.
	BB	EP 0 320 769	6/21/89	Europe			See AB above.
	BC	EP 0 446 616	9/18/91	Europe			See AC above.
	BD	WO 94/12761	6/9/94	WIPO			English
	BE	WO 96/08672	3/21/96	WIPO			English
	BF	EP 0 736 130	10/9/96	Europe			English
	BG	WO 96/41785	12/27/96	WIPO			English
	BH	EP 0 824 631	2/25/98	Europe			English
	BI	WO 98/23792	6/4/98	WIPO			See AL above.
	BJ	WO 98/23843	6/4/98	WIPO			English
	BK	WO 99/13197	3/18/99	WIPO			English
	BL	EP 0 914 407	5/12/99	Europe			See AI above.
	BM	EP 0 946 788	10/6/99	Europe			See AL above.
	BN	DE 199 20 152	10/12/00	Germany			See AP above.
	BO	WO 00/78706	12/28/00	WIPO			English
	BP	DE 199 30 683	1/18/01	Germany			See AN above.
	BQ	WO 01/09082	2/8/01	WIPO			English
	BR	DE 100 59 816	4/18/02	Germany			See AR above.
	BS	DE 101 14 638	5/23/02	Germany			See AQ above.
	BT						
	BU						
	BV						
	BW						
	BX						
	BY						
	BZ						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication\*\*)

	CA		
	CB		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			